A novel compound heterozygous mutation in TTC8 identified in a Japanese patient

Download PDF Data Report Open access Published: 12 March 2019 A novel compound heterozygous mutation in TTC8 identified in a Japanese patient Shigeru Sato1, Takeshi Morimoto1,2, Kikuko

Hotta3, Takashi Fujikado1,2 & …Kohji Nishida1 Show authors Human Genome Variation volume 6, Article number: 14 (2019) Cite this article

1612 Accesses

Metrics details

Bardet–Biedl syndrome (BBS), characterized by rod-cone dystrophy, postaxial polydactyly, central obesity, hypogonadism, renal abnormalities, and mental retardation, is a rare autosomal

recessive disorder. To date, 21 causative genes have been reported. Here we describe a Japanese BBS patient with a novel compound heterozygous mutation in TTC8. To the best of our knowledge,

this is the first description of a BBS patient with a mutation in the TTC8 gene in Japan.

Bardet–Biedl syndrome (BBS) is a rare autosomal recessive disorder characterized by rod-cone dystrophy, postaxial polydactyly, central obesity, hypogonadism, renal abnormalities, and mental

retardation. BBS is often complicated by strabismus/cataracts/astigmatism, diabetes mellitus, Hirschsprung disease, heart disease, and/or liver fibrosis. To date, 21 causative genes have

been reported, comprising ~80% of BBS genetic abnormalities1,2. The remaining 20% of genetic abnormalities among BBS patients are not yet known. In the present study, we performed

whole-exome sequencing (WES) of a classical BBS patient.

The patient was diagnosed with BBS at 8 years of age, in accordance with criteria reported previously3. Primary and secondary signs of BBS in this patient are listed in Table 1. When the

patient first visited Osaka University Hospital at 17 years of age, his best-corrected visual acuity (BCVA) was 0.07 in the right eye and 0.2 in the left eye. At 28 years of age, his BCVA

was 0.01 in the right eye and 0.04 in the left eye; he exhibited bilateral diffuse retinal degeneration, including macular atrophy, attenuated retinal vessels, and optic nerve head pallor

with little pigmentary dispersion. His parents were not consanguineous. His mother showed no sign of BBS or rod-cone dystrophy. His father did not have symptoms of BBS.

and secondary signs of BBS in this patientFull size table

All experimental procedures were approved by the Ethics Committee at Osaka University (No. 719–2, Osaka, Japan) and conducted in accordance with the Declaration of Helsinki. Written informed

consent was obtained from the patient (at the time of the report, a 28-year-old male) and his 61-year-old mother. Both individuals underwent ophthalmologic examinations: BCVA in decimal

units, slit-lamp biomicroscopy, fundoscopy, visual field testing with Goldmann perimetry, optical coherence tomography (SSOCT; DRI OCT1, Topcon Corp., Tokyo, Japan), and fundus

autofluorescence (Optos, Optos KK, Tokyo, Japan). Genomic DNA was extracted from blood samples using NucleoSpin Blood XL (Macherey-nagel, Düren, Germany). DNA libraries were constructed

using SureSelectXT Human All Exon Kit V6 and SureSelectXT Reagent Kit (Agilent, Santa Clara, CA, USA) and then subjected to 100 bp paired-end sequencing on an Illumina HiSeq2500 Platform

(Illumina, San Diego, CA, USA). Sequence reads were aligned to the reference human genome (UCSC hg19) in BWA (http://www.bio-bwa.sourceforge.net/) to align short reads after adaptor

sequences were removed by Cutadapt (https://cutadapt.readthedocs.io/en/stable/). SAM tools (Version 0.1.17; http://www.samtools.sourceforge.net/) were used for sequence data conversion,

sorting, and indexing. To exclude duplicate reads, Picard (http://picard.sourceforge.net) was used. Variants were determined using GATK (http://www.broadinstitute.org/gatk/). ANNOVAR

(http://www.openbioinformatics.org/annovar/) was used to annotate the resulting genetic variants. Rare variants (minor allele frequency < 0.05) were selected using the Exome Sequencing

Project, 1000 Genomes Project, and Human Genetic Variation databases; possible pathogenic variants, such as nonsynonymous, nonsense, and frameshift mutations, were extracted from among the

retinal degenerative disease-related genes registered in the Ret.Net.TM database.

Ten candidate pathogenic rare variants in genes related to retinal degenerative diseases were detected in this patient. All were heterozygous variants; however, two novel nonsense

(NM_001288781.1 [TTC8_v001]: c.226 C > T, p.Q76X) and frameshift (NM_001288781.1 [TTC8_v001]: c.309_310insTA, p.T103fs) mutations were located in the TTC8 gene (also known as BBS8). Both

mutations were validated by direct sequencing of PCR products (Applied Biosystems 3730 DNA Analyzer; Thermo Fisher Scientific K.K., Tokyo, Japan). The primer sets used for PCR were as

follows: c.226 C > T, 5′-TGGGTTTTAGGCAGCTTGGA-3′ and 5′-ACCATAAGGCAGAACAGAAACCA-3′; c.308_309insAT, 5′-TAGGCCCTGGAACGTCTTTG-3′ and 5′- ACCATAAGGCAGAACAGAAACCA-3′. This mutation is likely to

be pathogenic, because the TTC8 gene has been reported as a causative gene for BBS84. The nonsense mutation was located in exon 3 of the TTC8 gene, thus producing a truncated protein without

tetratricopeptide repeats 11 and 15, which are involved in pilus formation and twitching mobility. The frameshift mutation in exon 5 (c.309_310insTA) generates a premature stop codon in

exon 6, which also produces TTC8 lacking normal tetratricopeptide repeats 11 and 15. The premature stop codon is located before the last exon; notably, a mRNA transcribed from a gene with a

truncating mutation often undergoes nonsense-mediated mRNA decay before translation5. Thus, transcripts with nonsense and frameshift mutations are likely to be rapidly degraded to reduce the

translation of the truncated TTC8 protein. Therefore, this compound heterozygous patient would not have a functional TTC8 protein to support the formation of the BBSome, leading to the

development of BBS. His mother exhibited the heterozygous nonsense mutation, but no frameshift mutation. Although the genetic and clinical data were not available from his father, this

patient’s BBS was determined to result from a compound heterozygous TTC8 gene mutation.

BBS patients with mutations in the TTC8 gene comprise only 2.8% of all BSS patients6,7. In Japan, the genetics of four BBS families have been reported: BBS2, BBS5, and BBS7 homozygotes, as

well as a BBS10 compound heterozygote8,9. To the best of our knowledge, this is the first BBS patient with a mutation in the TTC8 gene in Japan. Thus far, 16 families with the TTC8 genetic

abnormality have been reported (Table 2)4,7,10,11,12,13,14,15. Most of these families have homozygous mutations; only our patient and a Hispanic family were compound heterozygotes. Although

full clinical information was not available for some cases, most of the cases in these 16 families exhibit classical BBS without obvious differences in phenotypes.

variants and phenotype reported in patients of BBS8Full size table

In summary, we identified a novel compound heterozygous mutation in a Japanese BBS patient by WES. Our findings suggest that WES may be a useful tool for genetic diagnosis and

characterization of BBS.

The relevant data from this Data Report are hosted at the Human Genome Variation Database at https://doi.org/10.6084/m9.figshare.hgv.2528; https://doi.org/10.6084/m9.figshare.hgv.2531

References Forsythe, E., Kenny, J., Bacchelli, C. & Beales, P. L. Managing Bardet-Biedl Syndrome-now and in the future. Front. Pediatr. 6, 23 (2018).

Article  Google Scholar 

Dilan, T. L. et al. Bardet-Biedl syndrome-8 (BBS8) protein is crucial for the development of outer segments in photoreceptor neurons. Hum. Mol. Genet. 15, 283–294 (2018).

Article  Google Scholar 

Beales, P. L., Elcioglu, N., Woolf, A. S., Parker, D. & Flinter, F. A. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J. Med. Genet. 36,

437–446 (1999).

CAS  PubMed  PubMed Central  Google Scholar 

Ansley, S. J. et al. Basal body dysfunction is a likely cause of pleiotropic Bardet-Biedl syndrome. Nature 425, 628–633 (2003).

Article  CAS  Google Scholar 

Hug, N., Longman, D. & Cáceres, J. F. Mechanism and regulation of the nonsense-mediated decay pathway. Nucleic Acids Res. 44, 1483–1495 (2016).

Article  Google Scholar 

Bin, J. et al. BBS7 and TTC8 (BBS8) mutations play a minor role in the mutational load of Bardet-Biedl syndrome in a multiethnic population. Hum. Mutat. 30, E-737–E746 (2009).

Article  Google Scholar 

Stoetzel, C. et al. BBS8 is rarely mutated in a cohort of 128 Bardet-Biedl syndrome families. J. Hum. Genet. 51, 81–84 (2006).

Article  Google Scholar 

Hirano, M. et al. The first nationwide survey and genetic analysis of Bardet-Biedl syndrome in Japan. PLoS ONE 10, e0136317 (2015).

Article  Google Scholar 

Kurata, K. et al. Clinical characteristics of a Japanese patient with Bardet-Biedl syndrome caused by BBS 10 mutations. Jpn J. Ophthalmol. 62, 458–466 (2018).

Article  CAS  Google Scholar 

Smaoui, N. et al. Screening of the eight BBS genes in Tunisian families: no evidence of triallelism. Invest. Ophthalmol. Vis. Sci. 47, 3487–3495 (2006).

Article  Google Scholar 

Harville, H. M. et al. Identification of 11 novel mutations in eight BBS genes by high-resolution homozygosity mapping. J. Med. Genet. 47, 262–267 (2010).

Article  CAS  Google Scholar 

Janssen, S. et al. Mutation analysis in Bardet-Biedl syndrome by DNA pooling and massively parallel resequencing in 105 individuals. Hum. Genet. 129, 79–90 (2011).

Article  CAS  Google Scholar 

Redin, C. et al. Targeted high-throughput sequencing for diagnosis of genetically heterogeneous diseases: efficient mutation detection in Bardet-Biedl and Alström syndromes. J. Med. Genet.

49, 502–512 (2012).

Article  CAS  Google Scholar 

M’hamdi, O. et al. Clinical and genetic characterization of Bardet-Biedl syndrome in Tunisia: defining a strategy for molecular diagnosis. Clin. Genet. 85, 172–177 (2014).

Article  Google Scholar 

Ullah, A. et al. Sequence variants in four genes underlying Bardet-Biedl syndrome in consanguineous families. Mol. Vis. 23, 482–494 (2017).

CAS  PubMed  PubMed Central  Google Scholar 

Download references

We thank E. Suga, M. Morita, Y. Hasegawa, S. Tanaka, and S. Ishino for their technical assistance. We thank Editage (www.editage.jp) for the English language editing. This research was

supported by the Project Promoting Clinical Trials for the Development of New Drugs and Medical Devices (Japan Medical Association) from the Japan Agency for Medical Research and

Development, AMED.

Author informationAuthors and Affiliations Department of Ophthalmology, Osaka University Graduate School of Medicine, Osaka, Japan

Shigeru Sato, Takeshi Morimoto, Takashi Fujikado & Kohji Nishida

Department of Applied Visual Science, Osaka University Graduate School of Medicine, Osaka, Japan

Takeshi Morimoto & Takashi Fujikado

Department of Medical Innovation, Osaka University Hospital, Osaka, Japan

Kikuko Hotta

AuthorsShigeru SatoView author publications You can also search for this author inPubMed Google Scholar

Takeshi MorimotoView author publications You can also search for this author inPubMed Google Scholar

Kikuko HottaView author publications You can also search for this author inPubMed Google Scholar

Takashi FujikadoView author publications You can also search for this author inPubMed Google Scholar

Kohji NishidaView author publications You can also search for this author inPubMed Google Scholar

Corresponding author Correspondence to Shigeru Sato.

The authors declare that they have no conflict of interest.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or

format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or

other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in

the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the

copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this articleCite this article Sato, S., Morimoto, T., Hotta, K. et al. A novel compound heterozygous mutation in TTC8 identified in a Japanese patient. Hum Genome Var 6, 14 (2019).

https://doi.org/10.1038/s41439-019-0045-y

Download citation

Received: 24 November 2018

Revised: 24 December 2018

Accepted: 10 January 2019

Published: 12 March 2019

DOI: https://doi.org/10.1038/s41439-019-0045-y

Share this article Anyone you share the following link with will be able to read this content:

Get shareable link Sorry, a shareable link is not currently available for this article.

Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative